Pyrotinib-based treatments in HER2-positive breast cancer patients with brain metastases

Abstract Objectives Extensive application of anti-HER2 targeted therapy improves significantly the HER2-positive advanced breast cancer (BC) prognosis, however, it is still difficult to treat brain metastasis. In current study, we explored effective approaches via combining pyrotinib to treat brain metastasis in patients with HER2-positive advanced BC based upon clinical data. Materials and methods Current study included 61 HER2-positive BC patients with brain metastases (BM) who were treated by pyrotinib-based regimens. The systemic regimens included pyrotinib combined with capecitabine, pyrotinib combined with nab-paclitaxel, and pyrotinib combined with vinorelbine. Patients’ progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR) and objective response rate (ORR), as well as drug-related adverse events (AEs) in regard of each combination regimen were analyzed. Results Pyrotinib-based systemic therapy resulted in 8.6 months median PFS (mPFS) and 18.0 months median OS (mOS) among the BM patients. Regarding different regimens, the combination of pyrotinib with nab-paclitaxel was superior to the combination with capecitabine and vinorelbine with respect to PFS and OS. The central nervous system (CNS) ORR did not showcase significant difference among 3 regimens, however, nab-paclitaxel combined regimen obtained the best peripheral ORR (84.6%) (p ≤ .05). Conclusions Pyrotinib-based combination therapy is safe for HER2-positive brain metastasis treatment. Compared with vinorelbine or capecitabine, pyrotinib combined with nab-paclitaxel is more effective with less toxicity, which is the preferable regimen for HER2-positive brain metastasis. KEY MESSAGES Present investigation investigated effective methods through combining pyrotinib to treat brain metastasis with HER2-positive advanced brain cancer. The outcomes verified that pyrotinib-based combination therapy was safe and efficient to treat HER2-positive brain metastasis. Therefore, it is effective to treat brain metastasis applying anti-HER2 targeted therapies although pyrotinib showcases efficiency regarding its treatments for the metastasis.

[1]  Ting Dou,et al.  Effects of rifampicin on antineoplastic drug pyrotinib maleate pharmacokinetics in healthy subjects , 2022, Investigational new drugs.

[2]  Ming Yan,et al.  Pyrotinib plus capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases (PERMEATE): a multicentre, single-arm, two-cohort, phase 2 trial. , 2022, The Lancet. Oncology.

[3]  E. Zhou,et al.  Pyrotinib Treatment in Patients With HER2-positive Metastatic Breast Cancer and Brain Metastasis: Exploratory Final Analysis of Real-World, Multicenter Data , 2021, Clinical Cancer Research.

[4]  Mafalda Oliveira,et al.  Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies , 2021, Cancers.

[5]  Yueyue Liu,et al.  Multiple Administrations of Itraconazole Increase Plasma Exposure to Pyrotinib in Chinese Healthy Adults , 2021, Drug design, development and therapy.

[6]  B. Shao,et al.  Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study , 2021, Frontiers in Oncology.

[7]  Wanqing Chen,et al.  Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020 , 2021, Chinese medical journal.

[8]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[9]  R. Soffietti,et al.  Management of Brain and Leptomeningeal Metastases from Breast Cancer , 2020, International journal of molecular sciences.

[10]  Xiaoxiao Luo,et al.  Pyrotinib enhances the radiosensitivity of HER2-overexpressing gastric and breast cancer cells , 2020, Oncology reports.

[11]  B. Kiely,et al.  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) , 2020, Annals of Oncology.

[12]  Kai-jing Zhao,et al.  Population pharmacokinetic modeling of pyrotinib in patients with HER2-positive advanced or metastatic breast cancer , 2020, medRxiv.

[13]  N. Lin,et al.  A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer , 2020, Clinical Cancer Research.

[14]  Sung-Bae Kim,et al.  Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  P. Ellis,et al.  Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  I. Kim,et al.  Evolving treatment strategies of brain metastases from breast cancer: current status and future direction , 2020, Therapeutic advances in medical oncology.

[17]  E. Winer,et al.  Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  S. Rhie,et al.  Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: A meta-analysis , 2020, Scientific Reports.

[19]  R. Schiff,et al.  Towards personalized treatment for early stage HER2-positive breast cancer , 2019, Nature Reviews Clinical Oncology.

[20]  R. Greil,et al.  Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. , 2019, The New England journal of medicine.

[21]  K. Jerzak,et al.  Central nervous system-specific efficacy of CDK4/6 inhibitors in randomized controlled trials for metastatic breast cancer , 2019, Oncotarget.

[22]  Xiaowei Qi,et al.  Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer. , 2019, American journal of cancer research.

[23]  Wei Li,et al.  Pyrotinib or Lapatinib Combined With Capecitabine in HER2-Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Lockman,et al.  Improving CNS Delivery to Brain Metastases by Blood-Tumor Barrier Disruption. , 2019, Trends in cancer.

[25]  H. Yao,et al.  Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. , 2019, Journal of Clinical Oncology.

[26]  Eric P. Winer,et al.  Breast Cancer Treatment: A Review , 2019, JAMA.

[27]  H. Rugo,et al.  Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs , 2018, Clinical Cancer Research.

[28]  Hannah A. Blair.  Pyrotinib: First Global Approval , 2018, Drugs.

[29]  Sarat Chandarlapaty,et al.  Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Xin Li,et al.  Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer , 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[31]  P. Lockman,et al.  Trastuzumab distribution in an in-vivo and in-vitro model of brain metastases of breast cancer. , 2017, Oncotarget.

[32]  S. Bates,et al.  Current challenges in the management of breast cancer brain metastases. , 2017, Seminars in oncology.

[33]  Xiaoyan Chen,et al.  Metabolic characterization of pyrotinib in humans by ultra-performance liquid chromatography/quadrupole time-of-flight mass spectrometry. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[34]  Miguel Martín.  nab-Paclitaxel dose and schedule in breast cancer , 2015, Breast Cancer Research.

[35]  V. Adamo,et al.  Efficacy of nab-paclitaxel plus trastuzumab in a long-surviving heavily pretreated HER2-positive breast cancer patient with brain metastases , 2015, OncoTargets and therapy.

[36]  R. Weil,et al.  Capecitabine and lapatinib uptake in surgically resected brain metastases from metastatic breast cancer patients: a prospective study. , 2015, Neuro-oncology.

[37]  S. Hurvitz,et al.  nab-Paclitaxel in combination with biologically targeted agents for early and metastatic breast cancer. , 2014, Cancer treatment reviews.

[38]  M. Desilvio,et al.  A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer , 2014, Breast Cancer Research and Treatment.

[39]  N. Lin,et al.  CNS Metastases in Breast Cancer: Old Challenge, New Frontiers , 2013, Clinical Cancer Research.

[40]  Erin M. Olson,et al.  Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  T. Cosgriff,et al.  A phase II study of weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab in metastatic breast cancer. , 2011, Clinical breast cancer.

[42]  J. Bergh,et al.  Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Michael Hawkins,et al.  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  V. Kaklamani,et al.  HER2-Positive Breast Cancer , 2012, Drugs.

[45]  H. Iwase,et al.  [Breast cancer]. , 2006, Nihon rinsho. Japanese journal of clinical medicine.